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ABSTRACT
Introduction: Rare cases of thrombotic
microangiopathy (TMA), manifested as
thrombotic thrombocytopenic purpura (TTP)
or hemolytic uremic syndrome (HUS), have
been reported with interferon b products. We
performed a cumulative review of TMA cases
recorded in a Global Safety Database for
patients with multiple sclerosis who received
subcutaneous interferon b-1a treatment.
Methods: Search criteria were: all reported
cases, serious and non-serious, from all sources
(including non-health care professionals and
clinical trial reports), regardless of event ranking
and causality assessment by reporter or
company. Data lock was May 3, 2014, with
additional analysis of cases reported between
August 1, 2014–November 30, 2014.
Results: Ninety-one patient cases (76.9%
female) with 105 events were retrieved. Time
to onset varied from 2 months to 14 years, and
in 31.9% of patients the event occurred within
2 years of treatment initiation. Seven patients
had a fatal outcome (five were secondary to
other causes and two reported insufficient
information). Forty-four patients recovered, 32
patients had not recovered at the time of the
report, and in eight cases outcome was either
not reported or unknown. Treatment was
discontinued in 84.6% (77/91) of patients. In
67% (61/91) of patients, the reporter suspected
a causal association between treatment and
TMA/TTP-HUS. Risk factors and/or
confounding factors were present in 45.1%
(41/91) of patients. Early prodromal syndrome
or specific patterns were not detected, although
54.9% (50/91) of cases contained insufficient
information. Overall reporting rate of TMA/
TTP-HUS was estimated as 7.2 per 100,000
patient-years. Reporting rates for human
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serum album (HSA)-containing and HSA-free
formulations were 5.72 and 7.68 per 100,000
patient-years, respectively.
Conclusion: No new signal relating specifically
to increased frequency of TMA/TTP-HUS with
HSA-free subcutaneous interferon b-1a was
detected and no additional risk mitigation
measures are required regarding the different
formulations. The benefit–risk balance of
subcutaneous interferon b-1a remains positive,
and routine pharmacovigilance monitoring is
appropriate.
Funding: Ares Trading SA, Aubonne,
Switzerland, a subsidiary of Merck Serono SA.
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INTRODUCTION
Interferon (IFN) b is a widely prescribed
recombinant-protein therapy with a well-
established, favorable safety profile. However,
rare cases of thrombotic microangiopathy
(TMA) have been associated with different IFN
b formulations, including intramuscular IFN b-
1a, subcutaneous (sc) IFN b-1a, and sc IFN b-1b
[1, 2].
TMA is a pathology expressed as
thrombocytopenia, microangiopathic hemolytic
anemia, and microvascular occlusion. TMA is
common to a number of disorders, including
hemolytic uremic syndrome (HUS), thrombotic
thrombocytopenic purpura (TTP), malignant
hypertension, and renal transplantation. TTP
and HUS have distinct pathophysiologies and
diagnoses, but there is considerable clinical
overlap [3]. In many case reports and series,
diagnostic uncertainty exists as ADAMTS 13 (von
Willebrand factor-cleaving protease) levels are
generally not available, prompting the use of
the composite term TTP-HUS [3]. TTP-HUS is
characterized by renal insufficiency, neurologic
impairment, and fever [4], and risk factors include
older age [5], female gender [5], systemic lupus
erythematosus [6], shiga toxin-producing bacteria
(e.g., Escherichia coli) [3], and concomitant
exposure to other treatments (e.g.,
chemotherapeutic agents, quinine/thiamine,
ticlopidine, ibuprofen) [7, 8].
The use of sc IFN b-1a (Rebif, EMD Serono
Inc.) is approved for the treatment of patients
with relapsing forms of multiple sclerosis (MS)
[9]. sc IFN b-1a has been marketed as a
formulation containing human serum albumin
(HSA) since February 5, 1998 in Canada, May 4,
1998 in the European Union (EU), and March 7,
2002 in the USA [9]. Since August and
September 2007, a HSA-free formulation of sc
IFN b-1a has been available in the EU and
Canada, respectively. The risk of TMA has been
described in the summary of product
characteristics (SmPC) for sc IFN b-1a since
2008 [10], and was included in both the EU
and US labels. More recently, a cluster of four
TMA cases associated with HSA-free sc IFN b-1a
was reported in South Scotland from 2010 to
2012 [11].
The aim of this cumulative review was to
characterize reports of TMA and TTP-HUS for
patients with MS who received sc IFN b-1a
(Rebif) from a Global Safety Database, and to
determine whether any differences in incidence
rates were associated with the introduction of
the HSA-free formulation of sc IFN b-1a in 2007.
METHODS
Reported cases of TMA, TTP, and HUS in
patients with MS who received sc IFN b-1a
(Rebif) were cumulatively reviewed in the
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Global Safety Database (Adverse Reaction
Information System global, ARISg; ArisGlobal,
CT, USA) for sc IFN b-1a (Rebif) treatment,
which comprises data for adverse events (AEs)
from clinical trials and post-marketing
surveillance reports. Search criteria were: all
reported cases, serious and non-serious, from all
sources (including non-health care
professionals and clinical trial reports),
regardless of event ranking and causality
assessment by reporter or company. The
database was searched using a custom Medical
Dictionary for Regulatory Activities (MedDRA
v17.0; the International Federation of
Pharmaceutical Manufacturers & Associations,
VA, USA) search strategy recommended by the
Pharmacovigilance Risk Assessment Committee
(European Medicines Agency) and developed to
capture TMA, TTP, and HUS, using the
following MedDRA codes: thrombotic





A data lock of May 3, 2014 was used to
account for the most recent Periodic Safety
Update Report. In addition, a time period of
August 1, 2014–November 30, 2014 was used to
assess the impact of reporting rates of TMA/TTP-
HUS following the circulation of a Dear
Healthcare Provider (DHCP) letter. At the
request of the European Medicines Agency, the
DHCP letter detailed the risks of, and need to
monitor for, TTP-HUS in patients treated with
sc IFN b-1a, and was circulated to healthcare
professionals between August 12, 2014 and
October 3, 2014 by manufacturers of sc IFN b-
1a (Bayer, Biogen Idec, Merck Serono, Novartis).
Overall and formulation (HSA-containing
and HSA-free) reporting rates for sc IFN b-1a
were calculated using medically and non-
medically confirmed patient cases and patient-
exposure data. Patient-exposure data were
derived from an internal sales source and
based on the number of sc IFN b-1a syringes
sold over a period of time. The HSA-containing
formulation reporting rate was calculated using:
total exposure minus HSA-free sc IFN b-1a
exposure. Calculation of formulation reporting
rates required assigning all patient case reports
to the relevant formulation. As the HSA-free
formulation is not available in the USA, all US
patient case reports were assigned to the HSA-
containing formulation. In countries where the
HSA-free formulation has replaced the HSA-
containing formulation, all events with an
onset date C6 months after the launch of the
new formulation were assumed to be related to
the HSA-free formulation.
The analysis in this article is based on
previously conducted clinical studies and post-
marketing surveillance reports, and does not
involve any new studies of human subjects or
animals. There was no change to the medical
management of patients, and no randomization
of participants to different groups.
Statistical analyses are descriptive and
further analyses of data were not feasible as
the Global Safety Database includes a
population of uncertain size.
RESULTS
Case Presentation: Data Lock May 3, 2014
In total, 91 serious patient cases were retrieved
with 105 serious events of TMA, TTP, and HUS
associated with sc IFN b-1a treatment; 83.8%
(n = 88/105) of events were medically
confirmed and 16.2% (n = 17/105) non-
medically confirmed. No patient cases or
events were non-serious. Most patients
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(n = 70/91; 76.9%) were female and mean age
was 44.5 years (range 17–73 years). Time to
onset ranged from 2 months to 14 years with a
mean of 4.5 years (n = 91; unknown = 20). In
31.9% (n = 29/91) of patient cases, the event
occurred within the first 2 years of treatment.
The distribution of patient cases reporting an
event according to formulation and year of
receipt generally increased over the defined
search period (Fig. 1). Patient cases were
geographically distributed across five
continents and more than half of cases were
reported in France and the USA: 33.0% USA;
20.9% France; 12.1% UK; 9.9% Germany; 7.6%
Canada; 4.4% Italy; 2.2% Spain; and 1.1% each
for Austria, Brazil, Finland, Greece, Iran, Japan,
Slovenia, Switzerland, Turkey.
Broadly, the search terms TMA, TTP, HUS,
and TP retrieved a similar number of patient
cases (Fig. 2). Seven of 91 patients reported TMA
with either TTP or HUS and 13 cases without
TTP or HUS. The non-search preferred terms
renal failure (n = 22/91; 24.2%) and
hypertension (n = 15/91; 16.5%) were
relatively frequent, while other non-search
preferred terms were relatively rare (Table S1
Fig. 1 Distribution of patient cases. a Distribution by year
of onset according to the formulations of sc IFN b-1a (not
shown are the 18 cases which were reported with no date of
adverse event onset: IFN b-1a formulation not known,
n = 10; HSA-containing sc IFN b-1a, n = 7; HSA-free sc
IFN b-1a, n = 1; combination, n = 0). b Distribution by
year of case receipt (independent of IFN b-1a formulation).
 Data for 2014 are locked at May 3. HSA human serum
albumin, IFN interferon, sc subcutaneous
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in the supplementary material). Early
prodromal syndrome or specific patterns were
not detected, although 54.9% (n = 50/91) of
patient cases had insufficient information
reported about the course of the event.
Seven of 91 (7.7%) patients had a fatal
outcome. Five of these deaths were secondary
to other causes (myocardial infarction, sepsis,
hemorrhagic shock, acute respiratory distress
syndrome, and septic/cardiogenic shock) and
the remaining two deaths had insufficient
information concerning the cause of death.
Of the 84 patients without a fatal outcome, 44
of 91 (48.4%) patients recovered, recovered
with sequelae, or were reported as recovering;
32 (35.2%) patients had not recovered at the
time of the report; and the outcome was not
reported or unknown in eight (8.8%) cases. sc
IFN b-1a treatment was discontinued in
84.6% (n = 77/91) patients, maintained in
7.7% (n = 7/91), and unknown in 6.6%
(n = 6/91). Treatment with sc IFN b-1a was
reintroduced in one patient without
recurrence of an event.
A causal association between sc IFN b-1a
treatment and TMA/TTP-HUS was suspected in
67.0% (n = 61/91) of cases, not suspected/not
related or unlikely in 13.2% (n = 12/91), not
reported/unknown in 18.7% (n = 17/91), and
‘‘not assessable’’ in one case. Risk factors and/or
confounding factors were present in 45.1%
(n = 41/91) of reported cases: 24.2% (n = 22/
91) prior or concomitant exposure to other
treatments (e.g., chemotherapeutic agents,
quinine/thiamine, and ibuprofen), 12.1%
(n = 11/91) hypertension, 4.4% (n = 4/91) use
of tobacco, 3.3% (n = 3/91)
hypercholesterolemia, and 2.2% (n = 2/91)
exposure to E. coli serotype. Other
risk/confounding factors were each listed in
two or fewer cases. For the remaining 54.9% of
patients with no confounders reported there
was generally insufficient information reported.
Case Presentation: August 1, 2014
to November 30, 2014
No increase in patient case reporting was
observed in the short period (August 1, 2014–
November 30, 2014) following circulation of
the DHCP letters. In total, six serious patient
cases were reported during the time period of
August 1, 2014 to November 30, 2014. Five
cases were reported following the circulation of
the DHCP letters from August 12, 2014: two
patient cases were reported in Germany and one
patient each in France, Netherlands, and
Canada.
Fig. 2 Percentage of patient cases described by the search term
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Patient characteristics for cases reported after
August 12, 2014 were similar to the May 3, 2014
data lock. Four of five patients were female.
TMA was reported in three cases, and TTP and
HUS were each reported in one case. No patients
had a fatal outcome. Three patients recovered or
were reported as recovering, one patient had
not recovered at the time of the report, and the
outcome was unknown in one case. sc IFN b-1a
treatment was discontinued in three patients,
maintained in one patient, and reintroduced in
one patient without recurrence of an event.
Reporting Rates
The estimated cumulative exposure to sc IFN
b-1a in the post-marketing setting as of May 3,
2014 was 1,259,436 patient-years. Overall
reporting rate of TMA/TTP-HUS, including
medically and non-medically confirmed
patient cases, was 7.2 per 100,000 patient-years
(n = 91/1,259,436).
Overall, 46 patients received the HSA-
containing formulation and 35 received the
HSA-free formulation (five patients received the
HSA-free formulation only and 30 patients had
received both formulations in countries where
the HSA-free formulation was launched);
10 patients had insufficient information
relating to the start date for the AE, and/or the
dates of sc IFN b-1a treatment, and were
therefore assessed as ‘unknown’ for the
formulation received at the time of the event.
All patients known to have received both
formulations experienced the onset of TMA-
related AEs[6 months after the launch date of
the new formulation, and were therefore all
considered as HSA-free sc IFN b-1a cases.
Estimated cumulative exposures for each
formulation in the post-marketing setting as of
May 3, 2014 were: HSA-free formulation,
455,535 patient-years; HSA-containing
formulation, 803,901 patient-years. Reporting
rates for the HSA-containing and HSA-free
formulations were 5.72 and 7.68 per 100,000
patient-years, respectively. The reporting rate
for the five patients receiving the HSA-free sc
formulation only (minus patients who received
both formulations) was 1.1 per 100,000 patient-
years.
DISCUSSION
Practice guidelines for TTP and TMA address the
difficulties in diagnosis of the disorders due to
overlap with autoimmune disease and state that
drugs (including quinine, estrogen-containing
medications, and pegylated IFN used to treat
hepatitis C) appear to be responsible for\15%
of all TTP cases [12]. Nevertheless, no fixed
guidelines exist for TMA cases associated with sc
IFN b-1a due to the rarity of the disorder and,
following a recent cluster of patient reports in
South Scotland [11], it was deemed that
research was required to identify any
differences in incidence rates associated with
the introduction of a HSA-free formulation of sc
IFN b-1a. The present cumulative review of
patient case reports from a Global Safety
Database for sc IFN b-1a treatment estimated
the overall reporting rate of TMA/TTP-HUS
(medically and non-medically confirmed) as
7.2 per 100,000 patient-years using patient-
exposure data up to May 3, 2014, which
further supports the rarity of TMA/TTP-HUS in
this patient population. In addition, no notable
association between increased frequency of
TMA/TTP-HUS and the HSA-free formulation
of sc IFN b-1a could be detected. Reporting rates
for the HSA-containing and HSA-free
formulations were comparable (5.72 and 7.68
per 100,000 patient-years, respectively), and
suggest that the increase in frequency of TMA/
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TTP-HUS associated with sc IFN b-1a treatment
is not associated with the introduction of the
HSA-free formulation.
Reporting of TMA associated with sc IFN b-1a
treatment generally increased per year over the
defined search period. Although the possibility
remains that this observation is related to a
specific increase in TTP-HUS associated with sc
IFN b-1a, we propose that it is instead related to
an overall increase in reporting of TMA in
general. In addition, using a separate, albeit
relatively short, period of August 1, 2014 to
November 30, 2014, we observed no increase in
reporting rates following the circulation of
DHCP letters between August 12, 2014 and
October 3, 2014, which suggests that TMA/TTP-
HUS was already well reported prior to the
safety update.
A number of patient characteristics resulting
from our dataset are worthy of discussion in
relation to the existing limited literature. The
majority (76.9%) of identified patient cases were
female, which is consistent with both the
underlying disease of MS and the limited
literature for TMA associated with sc IFN b-1a
treatment [2, 13]. Although reviews of case
reports have observed cases of early onset of
TMA presentation following sc IFN b-1a
treatment [2, 11], our dataset identified no
obvious prodromal syndrome; time to onset
varied from 2 months to 14 years, with a mean
of 4.5 years.
The presence of patient risk factors and
confounding factors should also be considered
in the rare reporting of TMA/TTP-HUS
associated with sc IFN b-1a treatment. Of 91
patients identified in our dataset, 45.1%
presented with risk factors and/or confounding
factors for TMA, including prior or concomitant
exposure to chemotherapeutic agents, quinine/
thiamine, and ibuprofen; hypertension; use of
tobacco; hypercholesterolemia; and exposure to
E. coli serotype. Ibuprofen is used to alleviate
flu-like symptoms in patients with MS during
treatment with IFN b-1a [14]. Case reports have
presented ibuprofen use in patients who
developed TMA [15] and TTP [16], although an
association has not been reported in patients
with MS who received sc IFN b-1a treatment.
Regarding E. coli exposure, recent cases of TMA/
TTP-HUS associated with sc IFN b-1a treatment
were reported in Canada [2] and Scotland [11],
and were not geographically localized. In
particular, Scotland is known to have higher
rates of infection with E. coli O157 than other
parts of the UK or Europe [17], and previous
surveillance of childhood HUS in Scotland
identified E. coli O157 in[90% of cases.
This cumulative review of a Global Safety
Database has some limitations. Statistical
analysis of data was not feasible as the
database includes a population of uncertain
size. Patient-exposure data are based on market
syringe sales and not patient use, while low
adherence or treatment holidays are not
accounted for. Consequently, calculation of
patient exposure from post-marketing data
tends to be underestimated. Due to the
difficulty in diagnosing TMA/TTP-HUS [12],
some cases may go unreported or may be
misdiagnosed. Analysis of data is reliant on
the reports included in the safety database and
may be affected by differences between
countries in reporting of AEs. Despite these
limitations, the majority of TMA/TTP-HUS cases
associated with sc IFN b-1a within the literature
are reported as case reports and this review
represents the first detailed analysis of the rare
condition in patients with MS.
Subcutaneous IFN b-1a has a well-
characterized safety profile and 20 years of
follow-up data [18–22], and the excellent
benefit–risk balance of sc IFN b-1a remains
positive. Results from this study alone do not
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suggest the need for additional risk mitigation
measures for different sc IFN b-1a formulations.
As no fixed guidelines exist for the diagnosis
and treatment of IFN b-1a-associated TMA, this
potential rare condition may be difficult to
diagnose and should be considered in MS
patients treated with IFN b-1a during routine
pharmacovigilance monitoring. Special
warnings and precautions in the SmPC include
monitoring for worsening angina, congestive
heart failure, or arrhythmia [10]. New clinical
presentation of hypertension or headache
should be evaluated carefully, and monitoring
of regular blood pressure is advised. Late-onset
cases have been characterized by headache,
hypertension, thrombocytopenia, and kidney
dysfunction [23, 24]. Latest advice from the
Medicines and Healthcare Products Regulatory
Agency includes vigilance for early symptoms
and prompt treatment [25], as early recognition
prevents cases from developing into a severe
event and death [12].
CONCLUSIONS
In this cumulative review of a Rebif Global Safety
Database, reporting rates show that no new signal
relating specifically to increased frequency of
TMA/TTP-HUS with HSA-free sc IFN b-1a was
detected. Routine pharmacovigilance will allow
further assessment of risk and confirmation
whether additional risk mitigation measures are
required. The benefit–risk balance of sc IFN b-1a
remains positive.
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